VASOMEDICAL INC
NT 10-Q, 1996-10-15
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: METRO GLOBAL MEDIA INC, 10QSB, 1996-10-15
Next: HISTORIC PRESERVATION PROPERTIES 1989 LIMITED PARTNERSHIP, 10-K/A, 1996-10-15



                     U.S. SECURITIES AND EXCHANGE COMMISSION
                                WASHINGTON, D.C.

                                   FORM 12b-25

         NOTIFICATION OF LATE FILING       SEC File Number: 0-18105

                            CUSIP Number ___________

[ ] Form 10-K and Form 10-KSB [ ] Form 20-F [X] Form 10-Q and Form 10-QSB [ ]
Form N-SAR

     For Period Ended:  August 31, 1996 [X]
     Transition  Report on Form 10-K [ ]
     Transition  Report  on Form  20-F [ ]  
     Transition  Report  on Form 11-K [ ]
     Transition  Report on Form 10-Q [ ] 
     Transition Report on Form N-SAR for the
     Transition Period Ended:_________________

=============================================================================

     Nothing in this form shall be  construed to imply that the  Commission  has
verified any information contained herein.

=============================================================================

     If the  notification  relates  to a portion of the  filing  checked  above,
identify the Item(s) to which the notification relates:


=============================================================================

Part I - Registrant Information

=============================================================================

Full Name of Registrant:           Vasomedical, Inc.
Former Name if applicable:
Address of Principal Executive Office:
                                   180 Linden Avenue
                                   Westbury, New York 11590
=============================================================================

Part II - Rules 12b-25(b) and (c)

=============================================================================

     If the subject  report could not be filed  without  unreasonable  effort or
expense  and  the  registrant  seeks  relief  pursuant  to Rule  12b-25(b),  the
following should be completed. [ ]

     (a) The reasons  described  in  reasonable  detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

     (b) The subject annual report,  semi-annual  report,  transition  report on
Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or
before the  fifteenth  calendar day following  the  prescribed  due date; or the
subject  quarterly report or transition  report on Form 10-Q, or portion thereof
will be filed on or before the fifth  calendar day following the  prescribed due
date; and

     (c) The accountant's statement or other exhibit required by Rule 12b- 25(c)
has been attached if applicable.


<PAGE>

==============================================================================

Part III - Narrative

==============================================================================

State below in  reasonable  detail the  reasons  why Form 10-K and Form 10-KSB,
20-F,  11-K, 10-Q and Form 10-QSB,  N-SAR,  or the transition report or portion
thereof could not be filed within the prescribed period.

Financial Statements Not Available.

==============================================================================

Part IV - Other Information

==============================================================================

     (1)  Name and telephone number of person to contact in regard to this
          notification:

              Joseph Giacalone                  (516) 997-4600
              Chief Financial Officer

     (2) Have all other periodic  reports  required under section 13 or 15(d) of
the Securities  Exchange Act of 1934 or section 30 of the Investment Company Act
of 1940  during the  preceding  12 months or for such  shorter  period  that the
registrant was required to file such report(s) been filed?  If the answer is no,
identify report(s).

              [X] Yes    [ ] No

     (3) Is it anticipated that any significant  change in results of operations
from the corresponding  period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?

              [ ] Yes    [X] No

     If so, attach an explanation of the anticipated  change,  both  narratively
and  quantitatively,  and, if  appropriate,  state the reasons why a  reasonable
estimate of the results cannot be made.

     Vasomedical,  Inc. has caused this  notification to be signed on its behalf
by the undersigned thereunto duly authorized.

Date: October 14, 1966                          By:/s/Joseph Giacalone   
                                                   Joseph Giacalone
                                                   Chief Financial Officer

==============================================================================

                                ATTENTION

     Intentional  misstatements or omissions of fact constitute Federal Criminal
Violations (See 18 U.S.C. 1001).



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission